Kyverna reports durable, safe CAR-T results as rivals face safety pauses

Key points

• Miv-cel showed durable benefits in 26 stiff person syndrome patients, with 92% remaining off chronic immunotherapies at one year.
• No high-grade cytokine release syndrome, ICANS, or IEC-HS events were recorded in over 100 patients across trials.
• Kyverna plans to include the new data in its rolling FDA submission, aiming for completion in Q4 2026.
• Novartis and BMS paused autoimmune CAR-T trials earlier in 2026 due to safety concerns, highlighting a potential competitive advantage for Kyverna's manufacturing approach.

Background

In late August 2026, Kyverna reported phase 1 results for miv-cel in rheumatoid arthritis, showing B cell depletion and clinical improvement with manageable safety profiles. This followed earlier news in September 2026 about safety pauses for Novartis and BMS autoimmune CAR-T programs due to inflammatory events. The current update extends these findings to long-term data in rare autoimmune conditions, reinforcing the safety narrative amidst industry-wide scrutiny of CAR-T manufacturing methods.

How outlets are covering it

Fierce Biotech emphasizes the stark contrast between Kyverna's clean safety profile and the recent setbacks at Novartis and BMS, attributing the difference to Kyverna's conventional manufacturing process versus the rapid platforms used by rivals. Endpoints News focuses on the regulatory implications, noting that the one-year data strengthens Kyverna's FDA submission for stiff person syndrome. STAT highlights the broader biotech landscape, framing Kyverna's success as a counterpoint to the safety challenges facing larger pharmaceutical companies in the autoimmune CAR-T space. BioSpace, while largely obscured by technical content in the provided source, aligns with the narrative of Kyverna approaching a potential first FDA-approved CAR-T for an autoimmune condition.

Why it matters

The data validates the potential of CD19 CAR-T therapies for autoimmune diseases, offering a single-dose alternative to chronic immunosuppression. It also underscores the importance of manufacturing methods in determining safety outcomes, a critical factor for regulators and investors evaluating the viability of this therapeutic class. If approved, miv-cel could redefine treatment standards for rare autoimmune disorders.

What to watch

Kyverna expects to complete its FDA rolling submission for miv-cel in stiff person syndrome by the end of Q4 2026. Enrollment for the phase 3 trial in generalized myasthenia gravis is on track to finish by mid-2027. The company is also exploring expansion into other neuroimmunology indications, such as progressive multiple sclerosis.